Multiplex HER2 and ER Co-Staining Assay for Tumor Heterogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for breast cancer classification and treatment selection, particularly for HER2-positive tumors, are limited by the inability to detect HER2 protein, estrogen receptor protein, and HER2 DNA simultaneously in a single sample, leading to incomplete understanding of tumor heterogeneity and potential resistance to targeted therapies.
Innovation Solution
A multiplex assay method that allows for the co-detection of HER2 protein, estrogen receptor protein, and HER2 genomic DNA on a single slide using specific antibodies and nucleic acid probes, enabling the visualization of each marker with different chromogens, thereby identifying individual cells with varying marker expressions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If separate single or dual marker assays are used to detect HER2 protein and ER protein, then the assay simplicity and ease of operation are maintained, but the ability to detect tumor heterogeneity and co-stain multiple markers simultaneously is lost
Solution Approach 1:
The patent combines multiple detection targets (HER2 protein, ER protein, and HER2 DNA) into a single multiplex assay performed on the same tissue section. Different chromogens are used to simultaneously visualize all three markers, enabling detection of tumor heterogeneity while maintaining operational simplicity through a unified assay protocol.
Solution Approach 2:
The patent segments the detection of different markers by using distinct chromogens (e.g., DAB for HER2 protein, Fast Red for ER protein, and silver acetate for HER2 DNA) that can be visually differentiated. This allows simultaneous detection of multiple markers while maintaining clear visual separation of signals.
2Measurement precision
If cell conditioning procedures for nucleic acid detection are applied, then HER2 DNA and chromosome 17 DNA can be detected, but the ability to detect proteins (HER2 and ER) is decreased due to protease digestion
Solution Approach 1:
The patent performs protein staining (IHC) for HER2 and ER proteins before performing nucleic acid hybridization (ISH) for HER2 DNA and chromosome 17 DNA. This preliminary action ensures that proteins are detected while still intact, as the subsequent nucleic acid detection steps do not require protease treatment that would degrade proteins.
Solution Approach 2:
The patent employs a dynamic, multi-step protocol where different detection methods are applied in a specific sequence: first protein detection with antibodies and chromogens, then nucleic acid detection with hybridization probes. This dynamic approach allows both protein and nucleic acid detection to be optimized without interference.
3Loss of information
If multiplex assay conditions are implemented to co-stain HER2 protein, ER protein, and HER2 DNA, then tumor heterogeneity can be detected, but the assay complexity and difficulty of detecting and measuring all markers simultaneously increases
Solution Approach 1:
The patent uses different chromogens that produce distinct colors or staining patterns for different markers: DAB (brown) for HER2 protein, Fast Red (red) for ER protein, and silver acetate (black) for HER2 DNA. This color differentiation allows simultaneous detection of multiple markers without significant interference, reducing the practical complexity of the multiplex assay.
Solution Approach 2:
The patent creates a universal assay platform that can detect multiple markers (proteins and nucleic acids) using a single integrated protocol. The same tissue section can be stained for all three targets simultaneously, eliminating the need for multiple separate assays and reducing overall workflow complexity despite the multi-target nature of the assay.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and accurate subtyping of breast tumors regarding HER2 status and estrogen receptor status, revealing tumor heterogeneity and guiding more effective treatment strategies by identifying cells that may not respond to standard therapies.
Implementation Method 1
contacting the sample with a HER2 protein-specific antibody and contacting the sample with an estrogen receptor protein-specific antibody
Implementation Method 2
contacting the sample with a HER2 genomic DNA-specific nucleic acid probe
Implementation Method 3
staining the HER2 protein with a first chromogen, the first chromogen is at a level effective to make HER2 protein visible and to block HER2 protein-specific antibody not bound by the secondary antibody
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Disclosed herein are methods for detecting the presence and/or amount of HER2 protein, HER2 nucleic acid (for example, HER2 genomic DNA), ER protein, and Chromosome 17 centromere DNA in a single sample. Samples stained for HER2 protein, HER2 DNA, ER protein, and Chromosome 17 DNA allow for the identification of various types of cancer cells, for example HER2 protein positive/ER protein positive/HER2 gene positive cells, HER2 protein positive/ER protein negative/HER2 gene positive cells, HER2 protein negative/ER protein positive/HER2 gene positive cells, and HER2 protein negative/ER protein negative/HER2 gene positive cells.